Chitosan/pshRNA Plasmid Nanoparticles Targeting MDR1 Gene Reverse Paclitaxel Resistance in Ovarian Cancer Cells

Overview

Journal J Huazhong Univ Sci Technolog Med Sci

Specialty General Medicine

Date 2009 Apr 29

PMID 19399413

Citations 5

Authors

Yan Yang

Zehua Wang

Minfang Li

Shi Lu

Affiliations

Soon will be listed here.

Abstract

In order to investigate the effect of chitosan/pshRNA plasmid nanoparticles targeting MDR1 genes on the resistance of A2780/TS cells to paclitaxel, chitosan/pshRNA plasmid nanoparticles were synthesized by means of a complex coacervation technique and transfected into A2780/TS cells. The cells transfected with MDR1-targeted chitosan/pshRNA plasmid nanoparticles were experimental cells and the cells transfected with chitosan/pGPU6/GFP/Neo no-load plasmid nanoparticles served as negative control cells. Morphological features of the nanoparticles were observed under transmission electron microscope (TEM). MDR1 mRNA expression was assessed by RT-PCR. Half-inhibitory concentration (IC50) of paclitaxel for A2780/TS cells was determined by MTT method. TEM showed that the nanoparticles were round-shaped, smooth in surface and the diameters varied from 80 to 120 nm. The MDR1 mRNA in the transfected cells was significantly decreased by 17.6%, 27.8% and 52.6% on the post-transfection day 2, 4 and 7 when compared with that in A2780/TS cells control (P<0.05). MTT assay revealed that the relative reversal efficiency was increased over time and was 29.6%, 51.2% and 61.3% respectively in the transfected cells 2, 4, 7 days after transfection and IC50 (0.197+/-0.003, 0.144+/-0.001, 0.120+/-0.004) were decreased with difference being significant when compared with that in A2780/TS (0.269+/-0.003) cells control (P<0.05). It was concluded that chitosan/pshRNA plasmid nanoparticles targeting MDR1 can effectively reverse the paclitaxel resistance in A2780/TS cells in a time-dependent manner.

Citing Articles

Dendritic cell engineering for selective targeting of female reproductive tract cancers.

Bhargava A, Srivastava R, Mishra D, Tiwari R, Sharma R, Mishra P Indian J Med Res. 2019; 148(Suppl):S50-S63.

PMID: 30964081 PMC: 6469378. DOI: 10.4103/ijmr.IJMR_224_18.

Engineered Nanoparticles Against MDR in Cancer: The State of the Art and its Prospective.

Ahmad J, Akhter S, Greig N, Kamal M, Midoux P, Pichon C Curr Pharm Des. 2016; 22(28):4360-4373.

PMID: 27319945 PMC: 5182049. DOI: 10.2174/1381612822666160617112111.

Evaluation of Chitosan-Tripolyphosphate Nanoparticles as a p-shRNA Delivery Vector: Formulation, Optimization and Cellular Uptake Study.

Karimi M, Avci P, Ahi M, Gazori T, Hamblin M, Naderi-Manesh H J Nanopharm Drug Deliv. 2016; 1(3):266-278.

PMID: 26989641 PMC: 4792291. DOI: 10.1166/jnd.2013.1027.

Optimizing molecular-targeted therapies in ovarian cancer: the renewed surge of interest in ovarian cancer biomarkers and cell signaling pathways.

Hiss D J Oncol. 2012; 2012:737981.

PMID: 22481932 PMC: 3306947. DOI: 10.1155/2012/737981.

Reversal of multi-drug resistance by vector-based-shRNA-mdr1 in vitro and in vivo.

Lu S, Huang Q, Wang Z, Song Y, Wang L J Huazhong Univ Sci Technolog Med Sci. 2009; 29(5):620-4.

PMID: 19821097 DOI: 10.1007/s11596-009-0517-2.

References

Borchard G . Chitosans for gene delivery. Adv Drug Deliv Rev. 2001; 52(2):145-50. DOI: 10.1016/s0169-409x(01)00198-3. View

Tajik H, Moradi M, Razavi Rohani S, Erfani A, Jalali F . Preparation of chitosan from brine shrimp (Artemia urmiana) cyst shells and effects of different chemical processing sequences on the physicochemical and functional properties of the product. Molecules. 2008; 13(6):1263-74. PMC: 6245338. DOI: 10.3390/molecules13061263. View

Katas H, Alpar H . Development and characterisation of chitosan nanoparticles for siRNA delivery. J Control Release. 2006; 115(2):216-25. DOI: 10.1016/j.jconrel.2006.07.021. View

Venkatesh S, Smith T . Chitosan-membrane interactions and their probable role in chitosan-mediated transfection. Biotechnol Appl Biochem. 1998; 27(3):265-7. View

Endicott J, Ling V . The biochemistry of P-glycoprotein-mediated multidrug resistance. Annu Rev Biochem. 1989; 58:137-71. DOI: 10.1146/annurev.bi.58.070189.001033. View

Guliyeva U, Oner F, Ozsoy S, Haziroglu R . Chitosan microparticles containing plasmid DNA as potential oral gene delivery system. Eur J Pharm Biopharm. 2005; 62(1):17-25. DOI: 10.1016/j.ejpb.2005.08.006. View

Shi Z, Liang Y, Chen Z, Wang X, Wang X, Ding Y . Reversal of MDR1/P-glycoprotein-mediated multidrug resistance by vector-based RNA interference in vitro and in vivo. Cancer Biol Ther. 2005; 5(1):39-47. DOI: 10.4161/cbt.5.1.2236. View

Mansouri S, Lavigne P, Corsi K, Benderdour M, Beaumont E, Fernandes J . Chitosan-DNA nanoparticles as non-viral vectors in gene therapy: strategies to improve transfection efficacy. Eur J Pharm Biopharm. 2004; 57(1):1-8. DOI: 10.1016/s0939-6411(03)00155-3. View

Gan H, Zhang G, Zhao J, Zhang F, Bu L, Yang S . Reversal of MDR1 gene-dependent multidrug resistance using short hairpin RNA expression vectors. Chin Med J (Engl). 2005; 118(11):893-902. View

10.

Xu C, Cai H, Xu Q, He P, Fang Y . Characterization of single-stranded DNA on chitosan-modified electrode and its application to the sequence-specific DNA detection. Fresenius J Anal Chem. 2001; 369(5):428-32. DOI: 10.1007/s002160000673. View

11.

Li C, Parker A, Menocal E, Xiang S, Borodyansky L, Fruehauf J . Delivery of RNA interference. Cell Cycle. 2006; 5(18):2103-9. DOI: 10.4161/cc.5.18.3192. View

12.

Aagaard L, Rossi J . RNAi therapeutics: principles, prospects and challenges. Adv Drug Deliv Rev. 2007; 59(2-3):75-86. PMC: 1978219. DOI: 10.1016/j.addr.2007.03.005. View

13.

Dastan T, Turan K . In vitro characterization and delivery of chitosan-DNA microparticles into mammalian cells. J Pharm Pharm Sci. 2004; 7(2):205-14. View

14.

Dai H, Jiang X, Tan G, Chen Y, Torbenson M, Leong K . Chitosan-DNA nanoparticles delivered by intrabiliary infusion enhance liver-targeted gene delivery. Int J Nanomedicine. 2007; 1(4):507-22. PMC: 1828073. DOI: 10.2147/nano.2006.1.4.507. View

15.

Wan Y, Zhang X, He Y, Jiang W . [Feasibility of chitosan as gene therapy vehicle]. Ai Zheng. 2006; 24(11):1408-11. View

16.

Zhao Q, Chen J, Han M, Liang W, Tabata Y, Gao J . Combination of poly(ethylenimine) and chitosan induces high gene transfection efficiency and low cytotoxicity. J Biosci Bioeng. 2008; 105(1):65-8. DOI: 10.1263/jbb.105.65. View

17.

Wu H, Hait W, Yang J . Small interfering RNA-induced suppression of MDR1 (P-glycoprotein) restores sensitivity to multidrug-resistant cancer cells. Cancer Res. 2003; 63(7):1515-9. View

18.

Kobayashi N, Matsui Y, Kawase A, Hirata K, Miyagishi M, Taira K . Vector-based in vivo RNA interference: dose- and time-dependent suppression of transgene expression. J Pharmacol Exp Ther. 2003; 308(2):688-93. DOI: 10.1124/jpet.103.059931. View

19.

You J, Liu Y, Peng C . Efficient gene transfection using chitosan-alginate core-shell nanoparticles. Int J Nanomedicine. 2007; 1(2):173-80. PMC: 2426794. DOI: 10.2147/nano.2006.1.2.173. View

20.

Chen X, Wang Q, Guan J, Huang Z, Zhang W, Zhang B . Reversing multidrug resistance by RNA interference through the suppression of MDR1 gene in human hepatoma cells. World J Gastroenterol. 2006; 12(21):3332-7. PMC: 4087887. DOI: 10.3748/wjg.v12.i21.3332. View